McDade, Eric http://orcid.org/0000-0002-6764-3866
Voytyuk, Iryna
Aisen, Paul
Bateman, Randall J. http://orcid.org/0000-0002-7729-1702
Carrillo, Maria C. http://orcid.org/0000-0003-3057-2387
De Strooper, Bart
Haass, Christian
Reiman, Eric M. http://orcid.org/0000-0002-0705-3696
Sperling, Reisa
Tariot, Pierre N. http://orcid.org/0000-0002-6058-8032
Yan, Riqiang
Masters, Colin L.
Vassar, Robert
Lichtenthaler, Stefan F.
Article History
Accepted: 23 July 2021
First Online: 21 September 2021
Competing interests
: There were no sources of funding that directly supported this work. E.M. reports serving on a data safety committee for Eli Lilly and Company, personal honoraria for continuing medical education activities for Eisai and Eli Lilly and Company and UpToDate, and institutional grant support from Eli Lilly and Company, Hoffman-La Roche and Janssen. P.A. has research grants from Eisai, Eli Lilly and Company and Janssen pharmaceuticals, and has received consulting fees from Biogen, Hoffman-La Roche, ImmunoBrain Checkpoint, Merck & Co. and Samus. R.J.B. serves as the principal investigator of the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU), which is supported by the Alzheimer’s Association, the GHR Foundation, an anonymous organization and the DIAN-TU Pharma Consortium (active: Biogen, Eisai, Eli Lilly and Company/Avid Radiopharmaceuticals, Hoffman-La Roche/Genentech, Janssen and United Neuroscience; previously: Abbvie, Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer and Sanofi). The DIAN-TU-001 clinical trial is supported by pharmaceutical partners Eli Lilly and Company, Hoffman-La Roche and Janssen, the Alzheimer’s Association, Avid Radiopharmaceuticals, the GHR Foundation, US National Institutes of Health (NIH) project U01AG042791, NIH project U01AG42791-S1 (Foundation for the National Institutes of Health Accelerating Medicines Partnership), NIH project R01AG046179, NIH project R56AG053267, NIH project R01AG053267, NIH project R01AG053267-S1, NIH project R01AG053267-S2, NIH project U01AG059798 and an anonymous organization. In-kind support has been received from Bracket and CogState for DIAN-TU-001. R.J.B. has received honoraria as a speaker and/or consultant and/or advisory board member from Amgen, AC Immune, Eisai, Hoffman-LaRoche, Janssen and Pfizer and reimbursement of travel expenses from AC Immune, Hoffman-La Roche and Janssen. R.J.B. receives laboratory research funding from the Alzheimer’s Association, the Association for Frontotemporal Degeneration, the BrightFocus Foundation, the Cure Alzheimer’s Fund, Centene Corporation, the NIH, the Rainwater Foundation Tau Consortium, the Tau SILK Consortium (AbbVie, Biogen and Eli Lilly and Company) and an anonymous foundation. R.J.B. is a cofounder of and serves on the scientific advisory board for C2N Diagnostics LLC. Washington University also holds equity in C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. Washington University, R.J.B. and D. Holtzman have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labelling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with R.J.B. as a co-inventor, has submitted the US non-provisional patent application “Methods for measuring the metabolism of CNS derived biomolecules in vivo” and the provisional patent application “Plasma based methods for detecting CNS amyloid deposition”. B.D.S. has received research support from Esai and Janssen pharmaceuticals. C.H. reports collaborations with Denali Therapeutics Inc., has participated in one advisory board meeting of Biogen and has received a speaker honorarium from Novartis and Roche. C.H. is the chief adviser to ISAR Bioscience. E.M.R. is one of the leaders of the Alzheimer’s Prevention Initiative, which worked closely with Amgen and Novartis in Alzheimer’s Prevention Initiative Generation Study 1 and Generation Study 2. These trials were funded by Amgen, the US National Institute on Aging, Novartis and philanthropy. E.M.R. is an unpaid scientific adviser to Avid Radiopharmaceuticals, a subsidiary of Eli Lilly and Company. R.S. has research grants from Eli Lilly and Company, Eisai and Janssen pharmaceuticals. P.N.T. has received consulting fees from Acadia, AC Immune, Axsome, BioXcel, Boehringer-Ingelheim, Brain Test Inc., Eisai, eNOVA, the Gerontological Society of America, Otuska & Astex and Syneos, consulting fees and research support from Abbvie, Avanir, Biogen, Cortexyme, Genentech, Eli Lilly and Company, Merck & Co. and Roche and research support from Novartis and has stock ownership in Adamas Pharmaceuticals, which has no past, current or known future involvement in any β-site amyloid precursor protein (APP)-cleaving enzyme (BACE) inhibitor-related therapies or clinical trials. R.V. has stock options in Alector given for his service on the scientific advisory board. R.V.’s advisory relationship with Alector does not involve BACE1 inhibition as a therapeutic strategy. R.V. has consulted for Eisai and Novartis in the past, but is not doing so currently. S.F.L. reports research funding from Novartis and Shionogi. The other authors report no relevant disclosures.